New hope: pill may stop remaining lung spots from becoming cancer

NCT ID NCT04591002

Recruiting now Disease control Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug osimertinib can stop small, hazy spots (called GGNs) in the lungs from growing after surgery for a specific type of lung cancer. About 43 adults with early-stage lung cancer and an EGFR mutation will take a daily pill for one year. The goal is to see if the spots shrink or stay stable, avoiding the need for more surgery or radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung adenocarcinoma lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

SMC
RECRUITING

Seoul, Kangnamgu, 06351, South Korea
Samsung medical center
SUSPENDED

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.